JAZZ 241220 80.00P (JAZZ241220P80000) Stock Options, News & Quotes

US OptionsDetailed Quotes

JAZZ241220P80000

Watchlist

0.20
-1.25-86.21%

15min DelayClose Nov 25 16:00 ET

0.20High0.05Low

Intraday

5D
Daily

News

A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $160 to $207
Moomoo NewsNov 22 08:00 ET · Ratings
Jazz Pharmaceuticals Insiders Sold US$1.7m Of Shares Suggesting Hesitancy
Simply Wall StNov 22 05:59 ET
Barclays Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
TipRanksNov 22 05:27 ET · Ratings
FDA Roundup: November 22, 2024
US FDANov 21 19:00 ET
Jazz Pharmaceuticals: Promising Growth Potential With Robust Pipeline and Undervalued Market Position
TipRanksNov 21 12:25 ET
Express News | FDA Grants Accelerated Approval to Zanidatamab-Hrii for Previously Treated Unresectable or Metastatic Her2-Positive Biliary Tract Cancer
ReutersNov 21 11:22 ET

Comments

Stock_Drift

Nov 20 18:32

$Jazz Pharmaceuticals (JAZZ.US)$

10xStockPicks

Oct 24 07:55

Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable

Esperion $Esperion Therapeutics (ESPR.US)$ We reiterate Strong Buy rating. Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 million Americans take statin drugs, we see continued prescription growth & expect over 5...

+20

Stock_Drift

Sep 16 06:45

$Jazz Pharmaceuticals (JAZZ.US)$

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

Moomoo AI

Mar 27 06:55

Despite Jazz Pharmaceuticals' revenue growth and profitability, its share price drop may signal unresolved issues. The long-term share price weakness could be a bad sign, yet contrarian investors might see a potential turnaround opportunity.

5.0% Earnings Growth Over 3 Years Has Not Materialized Into Gains for Jazz Pharmaceuticals (NASDAQ:JAZZ) Shareholders Over That Period